Sex differences in pharmacokinetics of antidepressants

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 2, 2011, Pages 213-226

  Kokras, Nikolaos ^a   Dalla, Christina ^a   Papadopoulou Daifoti, Zeta ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

cytochrome metabolism; depression; female; gonadal hormones; monoamine oxidase inhibitors; selective serotonin re uptake inhibitors; serotonin noradrenaline re uptake inhibitor; tetracyclic antidepressants; tricyclic antidepressants; women

Indexed keywords

ALBUMIN; ALPHA1 GLYCOPROTEIN; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DESIPRAMINE; DOSULEPIN; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GROWTH HORMONE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MULTIDRUG RESISTANCE PROTEIN 1; NEFAZODONE; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; REBOXETINE; SERTRALINE; SEX HORMONE; TRAZODONE; VENLAFAXINE;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; GENDER; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CYCLE; NONHUMAN; PHARMACOGENETICS; PHARMACOKINETICS; PRACTICE GUIDELINE; REVIEW; SEX DIFFERENCE;

AGING; ANTIDEPRESSIVE AGENTS; FEMALE; GONADAL HORMONES; HUMANS; MALE; SEX CHARACTERISTICS;

EID: 79952132249     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.544250     Document Type: Review

References (130)

1. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007;19(4):247-55 • Reviews data on sex differences in depression and antidepressant treatment, successfully addressing menstrual cycle, pregnancy and menopause issues.
2. Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am 2003;26(3):581-94 (Pubitemid 37175497)
3. Frackiewicz EJ, Sramek JJ, Cutler NR. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 2000;34(1):80-8 (Pubitemid 30058927)
4. Dalla C, Pitychoutis PM, Kokras N, et al. Sex differences in animal models of depression and antidepressant response. Basic Clin Pharmacol Toxicol 2010;106(3):226-33 • Reviews current state of experimental preclinical research on sex differences in the stress response and its modulation by antidepressants.
5. Dalla C, Antoniou K, Kokras N, et al. Sex differences in the effects of two stress paradigms on dopaminergic neurotransmission. Physiol Behav 2008;93(3):595-605 (Pubitemid 351208442)
6. Dalla C, Antoniou K, Drossopoulou G, et al. Chronic mild stress impact: are females more vulnerable? Neuroscience 2005;135(3):703-14
7. Bigos KL, Pollock BG, Stankevich BA, et al. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med 2009;6(4):522-43
8. Bies RR, Bigos KL, Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. J Gend Specif Med 2003;6(3):12-20 (Pubitemid 37098478)
9. Kornstein SG, McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. J Clin Psychiatry 2000;61(Suppl 11):18-27 (Pubitemid 30618038)
10. Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63(7):610-15
11. Kokras N, Antoniou K, Polissidis A, et al. Antidepressants induce regionally discrete, sex-dependent changes in brain's glutamate content. Neurosci Lett 2009;464(2):98-102
12. Pitychoutis PM, Griva E, Ioannou K, et al. Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage? Int J Neuropsychopharmacol 2009;12(9):1157-63
13. Kokras N, Antoniou K, Dalla C, et al. Sex-related differential response to clomipramine treatment in a rat model of depression. J Psychopharmacol 2009;23(8):945-56
14. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50(2):222-39
15. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 1996;21(2):123-8 (Pubitemid 26246155)
16. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 2005;14(1):19-29 (Pubitemid 40309363)
17. Dawkins K, Potter WZ. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacol Bull 1991;27(4):417-26
18. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(Suppl):23-33
19. Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000;22(2):143-54
20. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(1):85-102 (Pubitemid 36131110)
21. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154(7):963-9 (Pubitemid 27274539)
22. Schnoll RA, Patterson F. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. Drug Alcohol Depend 2009;104(Suppl 1):S94-9 •• Elegantly unmasks and explains the interaction between genes, sex and treatment.
23. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol 2008;83:1-10
24. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42(2):107-21 (Pubitemid 36188552)
25. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41(5):329-42
26. Thompson DS, Pollock BG. Psychotropic metabolism: gender-related issues. Psychiatr Times 2001;18:46-8
27. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31(5):403-13
28. Udechuku A, Nguyen T, Hill R, et al. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44(11):978-96
29. Kashuba AD, Nafziger AN, Kearns GL, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 1998;8(5):403-10 (Pubitemid 28475304)
30. Bennett EJ, Evans P, Scott AM, et al. Psychological and sex features of delayed gut transit in functional gastrointestinal disorders. Gut 2000;46(1):83-7 • Indicates how a psychiatric disorder may affect pharmacokinetics, an often neglected factor in studies with healthy volunteers.
31. Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev 2009;41(3):408-21
32. Kristensen CB. Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther 1983;34(5):689-94 (Pubitemid 14247729)
33. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34(3):203-18 •• A thorough explanation of how the menstrual cycle influences many parameters closely related to pharmacokinetics.
34. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci 2010;31(3):108-14 • An in-depth and explanatory review of sex differences generally in metabolism of drugs.
35. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009;76(2):215-28 •• The unravelling of a fascinating story from rats to humans regarding the sex-differentiated pattern of growth hormone secretion which ultimately affects drug metabolism.
36. Pitychoutis PM, Zisaki A, Dalla C, et al. Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des 2010;16(20):2214-23
37. Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 2003;26(9):799-813 (Pubitemid 38049162)
38. Martin G, Gan TJ. Gender difference: hype or fact? Semin Anesth Perioperat Med Pain 2000;19(2):76-82
39. Sinues B, Fanlo A, Mayayo E, et al. CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. Hum Exp Toxicol 2008;27(5):367-72 • Clearly shows how oral contraceptives induce CYP2A6 activity.
40. Higashi E, Fukami T, Itoh M, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35(10):1935-41 (Pubitemid 47481589)
41. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003;307(3):906-22 (Pubitemid 37494207)
42. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82(1):87-96 (Pubitemid 46944201)
43. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999;55(3):177-84 (Pubitemid 29244644)
44. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res 2007;55(2):81-95 (Pubitemid 46186037)
45. Court MH, Hao Q, Krishnaswamy S, et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 2004;310(2):656-65 (Pubitemid 38988911)
46. Physicians Desk Reference. Physicians' Desk Reference. 63rd edition. Thomson PDR, Montvale, NJ; 2009
47. Leinonen E, Lepola U, Koponen H, et al. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18(2):111-17 (Pubitemid 26104615)
48. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram - a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000;25(3):241-54 (Pubitemid 30641001)
49. Fudio S, Borobia AM, Pinana E, et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 2010;626(2-3):200-4
50. Jin Y, Pollock BG, Frank E, et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 2010;50(1):62-72
51. de Mendonca Lima CA, Baumann P, Brawand-Amey M, et al. Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):952-6 (Pubitemid 41080117)
52. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 2004;44(12):1352-9 (Pubitemid 39518640)
53. Le Bloc'h Y, Woggon B, Weissenrieder H, et al. Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Ther Drug Monit 2003;25(5):600-8
54. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit 2003;25(2):183-91
55. Reis M, Olsson G, Carlsson B, et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002;22(4):406-13 (Pubitemid 34810331)
56. Reis M, Cherma MD, Carlsson B, et al. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 2007;29(6):758-66 (Pubitemid 350190852)
57. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009;31(1):42-56 •• Unmasks pharmacokinetic sex differences regarding many antidepressants in adequately large patient samples.
58. Hodes GE, Hill-Smith TE, Suckow RF, et al. Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther 2010;332(1):266-73 •• Demonstrates experimentally the interaction between sex-differentiated pharmacokinetics and sex-dependent hippocampal neurogenesis.
59. Ferguson JM, Hill H. Pharmacokinetics of fluoxetine in elderly men and women. Gerontology 2006;52(1):45-50 (Pubitemid 43162720)
60. Jannuzzi G, Gatti G, Magni P, et al. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit 2002;24(5):616-27
61. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(Suppl 1):1-21
62. Hartter S, Wetzel H, Hammes E, et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998;20(4):446-9 (Pubitemid 28359997)
63. van den Broek WW, Birkenhager TK, Mulder PG, et al. Time-dependent clearance decrements of fluvoxamine in depressed inpatients: a clinical evaluation. J Clin Psychopharmacol 2007;27(2):231-3 (Pubitemid 46594955)
64. Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006;31(6):1274-85 (Pubitemid 43971843)
65. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 2004;60(8):553-7 (Pubitemid 39517907)
66. Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006;61(5):558-69
67. Reis M, Aberg-Wistedt A, Agren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 2004;19(5):283-91
68. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008;30(4):474-82
69. Alderman J, Wolkow R, Fogel IM. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):117-29
70. Almeida S, Portoles A, Terleira A, et al. Comparative bioavailability/bioequivalence of two different sertraline formulations: a randomised, 2-period x 2-sequence, crossover clinical trial in healthy volunteers. Arzneimittelforschung 2005;55(4):191-7 (Pubitemid 40562608)
71. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinetics 1997;32(Suppl 1):22-30 (Pubitemid 27107716)
72. Jannuzzo MG, Ryde M, Karlmark B, et al. P-2-77 pharmacokinetics of reboxetine in healthy volunteers of different ages. Eur Neuropsychopharmacol 1995;5(3):300
73. Fleishaker JC, Mucci M, Pellizzoni C, et al. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos 1999;20(1):53-7 (Pubitemid 29054654)
74. Ohman D, Cherma MD, Norlander B, et al. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit 2003;25(2):174-82 (Pubitemid 36373424)
75. Lobo ED, Quinlan T, O'Brien L, et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet 2009;48(3):189-97
76. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16(5):915-23 (Pubitemid 26322194)
77. Gex-Fabry M, Rudaz S, Balant-Gorgia AE, et al. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol 2002;58(5):323-31 • Indicates how sex may affect antidepressant pharmcokinetics in a stereoselective manner.
78. Reis M, Lundmark J, Bjork H, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002;24(4):545-53 (Pubitemid 34857910)
79. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001;41(7):770-8 (Pubitemid 32612441)
80. Daviss WB, Perel JM, Rudolph GR, et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry 2005;44(4):349-57 (Pubitemid 40393273)
81. Findlay JW, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21(2):127-35 (Pubitemid 12239647)
82. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37(8):737-43 (Pubitemid 27449283)
83. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35(9):876-84
84. Burrows G, Scoggins BA, Turecek LR, et al. Plasma nortriptyline and clinical response. Clin Pharmacol Ther 1974;16(4):639-44
85. Ziegler VE, Biggs JT. Tricyclic plasma levels. Effect of age, race, sex, and smoking. JAMA 1977;238(20):2167-9
86. Masubuchi Y, Iwasa T, Fujita S, et al. Regioselectivity and substrate concentration-dependency of involvement of the CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline in rat liver microsomes. J Pharm Pharmacol 1996;48(9):925-9 (Pubitemid 26364895)
87. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry 1985;46(7):276-7 (Pubitemid 15234395)
88. Hammer W, Sjoqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967;6(17):1895-903
89. Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982;15(1):56-61 (Pubitemid 12130459)
90. Dawling S, Crome P, Braithwaite R. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin Pharmacokinet 1980;5(4):394-401 (Pubitemid 10026856)
91. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996;123(4):315-9 (Pubitemid 26075783)
92. Nordin C. CSF/plasma ratio of 10-hydroxynortriptyline is influenced by sex and body height. Psychopharmacology (Berl) 1993;113(2):222-4 • Raises a valid and neglected concern regarding the presumed sex-dependent permeability of the blood - brain barrier to antidepressants.
93. Jerling M, Merle Y, Mentre F, et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994;38(5):453-62 (Pubitemid 24344034)
94. Schmider J, Deuschle M, Schweiger U, et al. Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic-pituitary-adrenal system function. J Clin Psychopharmacol 1995;15(4):250-8
95. King JN, Maurer MP, Altmann BO, et al. Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. Am J Vet Res 2000;61(1):80-5 (Pubitemid 30020652)
96. Lainesse C, Frank D, Beaudry F, et al. Comparative oxidative metabolic profiles of clomipramine in cats, rats and dogs: preliminary results from an in vitro study. J Vet Pharmacol Ther 2007;30(5):387-93 (Pubitemid 47366615)
97. Lainesse C, Frank D, Beaudry F, et al. Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration. J Vet Pharmacol Ther 2007;30(2):116-26 (Pubitemid 46365035)
98. Shimoda K, Jerling M, Bottiger Y, et al. Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 1999;19(5):393-400 (Pubitemid 29451503)
99. Mundo E, Bareggi SR, Pirola R, et al. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry 1999;45(3):290-4
100. Mundo E, Pirola R, Bellodi L, et al. Are gender differences in antiobsessional response related to different clomipramine metabolism? J Clin Psychopharmacol 2002;22(3):341-2
101. Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003;160(9):1643-50
102. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinetics 1990;19(3):241-55
103. Biegon A, Samuel D. The in vivo distribution of an antidepressant drug (DMI) in male and female rats. Psychopharmacology (Berl) 1979;65(3):259-63 (Pubitemid 10194752)
104. Wilson MA, Roy EJ. Pharmacokinetics of imipramine are affected by age and sex in rats. Life Sci 1986;38(8):711-18 (Pubitemid 16163949)
105. Pscheidt GR. Demethylation of imipramine in male and female rats. Biochem Pharmacol 1962;1:501-2
106. Nagy A, Treiber L. Quantitative determination of imipramine and desipramine in human blood plasma by direct densitometry of thin-layer chromatograms. J Pharm Pharmacol 1973;25(8):599-603
107. Masubuchi Y, Igarashi S, Suzuki T, et al. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. J Pharmacol Exp Ther 1996;279(2):724-31 (Pubitemid 27166845)
108. Chiba M, Nishihara E, Fujita S, et al. Position selective sex difference in imipramine metabolism in rat liver microsomes. Biochem Pharmacol 1985;34(6):898-900 (Pubitemid 15107186)
109. Fujita S, Morimoto R, Chiba M, et al. Evaluation of the involvement of a male specific cytochrome P-450 isozyme in senescence-associated decline of hepatic drug metabolism in male rats. Biochem Pharmacol 1989;38(22):3925-31 (Pubitemid 20008726)
110. Cohen LG, Biederman J, Wilens TE, et al. Desipramine clearance in children and adolescents: absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 1999;38(1):79-85 (Pubitemid 29022491)
111. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985;232(1):183-8 (Pubitemid 15193670)
112. Moody JP, Tait AC, Todrick A. Plasma levels of imipramine and desmethylimipramine during therapy. Br J Psychiatry 1967;113(495):183-93
113. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984;35(6):792-7 (Pubitemid 14077485)
114. Maguire KP, Norman TR, McIntyre I, et al. Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations. Clin Pharmacokinet 1983;8(2):179-85
115. Masubuchi Y, Konishi M, Horie T. Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes. Arch Toxicol 1999;73(3):147-51 (Pubitemid 29279500)
116. Reis M, Prochazka J, Sitsen A, et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit 2005;27(4):469-77 (Pubitemid 41098822)
117. Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol 1996;11(6):497-509 (Pubitemid 26423611)
118. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51(3):267-85 (Pubitemid 29202175)
119. Borobia AM, Novalbos J, Guerra-Lopez P, et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res 2009;59(6):393-8 • An example of an adequate design with enough statistical power to explore pharmacokinetic sex differences in healthy volunteers.
120. Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 1995;49(3):221-8
121. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16(1):19-25 (Pubitemid 26060752)
122. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997;33(4):260-75 (Pubitemid 27429893)
123. Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995;10(3):143-6
124. Prapotnik M, Waschgler R, Konig P, et al. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharmacol Ther 2004;42(2):120-4
125. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987;42(2):193-200 (Pubitemid 17135976)
126. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995;17(1):39-46
127. Pfuhlmann B, Gerlach M, Burger R, et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 2007;(72):287-96
128. Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999;37(11):529-47 (Pubitemid 29524971)
129. Tsai SJ, Gau YT, Hong CJ, et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009;113(1-2):183-7
130. Kornstein SG, Clayton AH, Soares CN, et al. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol 2010;30(3):294-9